Jermaine D. Jones

发表

Impact of in-patient research participation on subsequent heroin use patterns: implications for ethics and public health.

S. Vosburg, P. Saccone, Z. Cooper, 2012, Addiction.

The Epidemiology of Pain and Opioid Abuse

S. Comer, Jermaine D. Jones, Jermaine D Jones, 2016 .

Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

S. Vosburg, S. Comer, J. Manubay, 2012, Drug and alcohol dependence.

The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine’s effects

H. Kranzler, N. Vadhan, S. Comer, 2022, Behavioural pharmacology.

Opioid overdose reversals using naloxone in New York City by people who use opioids: Implications for public health and overdose harm reduction approaches from a qualitative study.

J. Strang, S. Parkin, S. Comer, 2020, The International journal on drug policy.

Emotional Reactions of Trained Overdose Responders who Use Opioids following Intervention in An Overdose Event

J. Strang, S. Parkin, S. Comer, 2021, Substance abuse.

Effects of Acute Oral Naltrexone on the Subjective and Physiological Effects of Oral D-Amphetamine and Smoked Cocaine in Cocaine Abusers

S. Vosburg, D. Martínez, P. Saccone, 2013, Neuropsychopharmacology.

The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid‐dependent volunteers

Kirk W. Johnson, M. Pavlicova, S. Vosburg, 2016, Addiction biology.

The pharmacogenetics of alcohol use disorder.

H. Kranzler, S. Comer, Jermaine D. Jones, 2015, Alcoholism, clinical and experimental research.

Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone

S. Vosburg, Z. Cooper, M. Sullivan, 2013, PAIN®.

Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans — pilot study outcomes

K. Hatton, S. Walsh, S. Comer, 2021, Psychopharmacology.

Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder

M. Sullivan, S. Comer, Jermaine D. Jones, 2017, Journal of psychoactive drugs.

Multi-informant Implementation and Intervention Outcomes of Opioid Overdose Education and Naloxone Distribution in New York City

Marie-Therese Schultes, S. Comer, A. Campbell, 2021, Global Implementation Research and Applications.

Dopamine, norepinephrine and serotonin transporter gene deletions differentially alter cocaine-induced taste aversion

G. Uhl, A. Riley, Jermaine D. Jones, 2010, Pharmacology Biochemistry and Behavior.

A randomized, double‐blind, placebo‐controlled study of the kappa opioid receptor antagonist, CERC‐501, in a human laboratory model of smoking behavior

E. Nunes, S. Walsh, S. Comer, 2020, Addiction biology.

Immunotherapeutic strategies for treating opioid use disorder and overdose

S. Comer, Jermaine D. Jones, M. Pravetoni, 2023, Expert opinion on investigational drugs.

A review of human drug self-administration procedures

S. Comer, Jermaine D. Jones, Jermaine D Jones, 2013, Behavioural pharmacology.

Polydrug abuse: a review of opioid and benzodiazepine combination use.

S. Comer, Sandra D Comer, Jermaine D. Jones, 2012, Drug and alcohol dependence.

A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City.

J. Strang, S. Parkin, S. Comer, 2020, The International journal on drug policy.

A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.

S. Vosburg, S. Comer, J. Manubay, 2013, Addiction.

Improving Translational Research Outcomes for Opioid Use Disorder Treatments

T. Hudzik, Jermaine D. Jones, A. Huhn, 2021, Current Addiction Reports.

Glial and neuroinflammatory targets for treating substance use disorders.

S. Comer, K. Heinzerling, Jermaine D. Jones, 2017, Drug and alcohol dependence.

Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion

G. Uhl, A. Riley, K. Rice, 2009, Pharmacology Biochemistry and Behavior.

Factor structure and psychometric properties of the Connor-Davidson resilience scale (CD-RISC) in individuals with opioid use disorder.

S. Batchelder, D. Hien, S. Comer, 2021, Drug and alcohol dependence.

Factors associated with withdrawal symptoms and anger among people resuscitated from an opioid overdose by take-home naloxone: Exploratory mixed methods analysis.

J. Strang, S. Parkin, S. Comer, 2020, Journal of substance abuse treatment.

Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and/or Alcohol Use

S. Comer, J. Gudin, Jermaine D. Jones, 2013, Postgraduate medicine.

The effects of cocaine, alcohol and cocaine/alcohol combinations in conditioned taste aversion learning

A. Riley, A. Verendeev, Jermaine D. Jones, 2005, Pharmacology Biochemistry and Behavior.

A randomized clinical trial of the effects of brief versus extended opioid overdose education on naloxone utilization outcomes by individuals with opioid use disorder.

J. Strang, S. Ross, S. Comer, 2022, Drug and alcohol dependence.

Strain-dependent sex differences in the effects of alcohol on cocaine-induced taste aversions

A. Riley, Jermaine D. Jones, Gregory D. Busse, 2006, Pharmacology Biochemistry and Behavior.

Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial

Marion A. Coe, S. Walsh, S. Comer, 2017, JAMA psychiatry.

The Increasing Prevalence of Fentanyl: A Urinalysis-Based Study Among Individuals With Opioid Use Disorder in New York City.

S. Comer, A. Campbell, Jermaine D. Jones, 2020, The American journal on addictions.

Fentanyl Withdrawal: Understanding Symptom Severity and Exploring the Role of BMI on Withdrawal Symptoms and Clearance.

S. Comer, C. J. Choi, Jermaine D. Jones, 2022, Addiction.

Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorder

S. Comer, A. Campbell, Jermaine D. Jones, 2020, Substance abuse.

Potential of Glial Cell Modulators in the Management of Substance Use Disorders

Jermaine D. Jones, Jermaine D Jones, 2020, CNS Drugs.

The Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Patients with Chronic, Non-Malignant Pain who are Maintained on Sublingual Buprenorphine/Naloxone

S. Vosburg, M. Sullivan, S. Comer, 2011, Neuropsychopharmacology.

Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts

William J. Kowalczyk, S. Vosburg, P. Saccone, 2013, Behavioural pharmacology.

A review of pharmacogenetic studies of substance-related disorders.

S. Comer, Jermaine D. Jones, 2015, Drug and alcohol dependence.

Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

S. Comer, Jermaine D. Jones, Jermaine D Jones, 2016, The American journal on addictions.

Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder.

F. Levin, S. Comer, J. Manubay, 2020, Drug and alcohol dependence.

Brief overdose education can significantly increase accurate recognition of opioid overdose among heroin users.

S. Stancliff, S. Comer, P. Roux, 2014, The International journal on drug policy.

Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential

R. Ciccocioppo, A. Bisaga, S. Comer, 2017, Pharmacology Biochemistry and Behavior.

The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users

R. Ciccocioppo, M. Sullivan, S. Comer, 2016, Physiology & Behavior.

Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount.

S. Comer, J. Manubay, Jermaine D. Jones, 2017, Drug and alcohol dependence.

The subjective experience of heroin effects among individuals with chronic opioid use: Revisiting reinforcement in an exploratory study

F. Levin, S. Comer, Jermaine D. Jones, 2022, Addiction neuroscience.

No evidence of accelerated epigenetic aging among black heroin users: A case vs control analysis.

Gabriel J. Odom, S. Comer, Jermaine D. Jones, 2023, Addiction neuroscience.

Understanding preferences for type of take-home naloxone device: international qualitative analysis of the views of people who use opioids

R. Dwyer, S. Fraser, J. Strang, 2021, Drugs.

How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken during overdose emergencies

J. Strang, S. Comer, A. Campbell, 2018, Addiction.

How competent are people who use opioids at Responding to overdoses? Qualitative analyses of actions and decisions taken by lay first-responders During overdose emergencies

J. Strang, S. Comer, A. Campbell, 2018 .

Chronic pain and opioid abuse: Factors associated with health‐related quality of life

S. Comer, Jermaine D. Jones, M. Mumtaz, 2017, The American journal on addictions.

Methylphenidate modifies the motion of the circadian clock Lamotrigine in mood disorders and cocaine dependence Cortical glutamate in postpartum depression Effects of Ibudilast on the Subjective , Reinforcing and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence

Kirk W. Johnson, M. Sullivan, S. Comer, 2017 .

The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety

R. Ciccocioppo, A. Bisaga, S. Comer, 2018, Journal of psychoactive drugs.

Glial modulators: a novel pharmacological approach to altering the behavioral effects of abused substances

Z. Cooper, S. Comer, Jermaine D. Jones, 2012, Expert opinion on investigational drugs.

The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users

S. Comer, Jermaine D. Jones, Jermaine D Jones, 2014, Pharmacology Biochemistry and Behavior.

Behavioral effects and drug vulnerability in rats exposed to Pfiesteria toxin.

A. Gordon, Jermaine D. Jones, B. Dyer, 2005, Neurotoxicology and teratology.

Changes in cardiac vagal tone as measured by heart rate variability during naloxone-induced opioid withdrawal.

S. Comer, Jermaine D. Jones, Charles J. Levin, 2019, Drug and alcohol dependence.

Effect of BuprenorphineWeekly Depot ( CAM 2038 ) and Hydromorphone Blockade in Individuals With Opioid Use Disorder A Randomized Clinical Trial

Marion A. Coe, S. Walsh, S. Comer, 2017 .

The effects of heroin administration and drug cues on impulsivity

N. Vadhan, S. Comer, Jermaine D. Jones, 2016, Journal of clinical and experimental neuropsychology.

Oxycodone abuse in New York City: characteristics of intravenous and intranasal users.

S. Vosburg, S. Comer, J. Manubay, 2011, The American journal on addictions.

Sex Differences Among Opioid-Abusing Patients With Chronic Pain in a Clinical Trial

S. Vosburg, M. Sullivan, S. Comer, 2015, Journal of addiction medicine.

Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine‐maintained heroin users

M. Sullivan, S. Comer, Jermaine D. Jones, 2015, Addiction biology.

No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone.

S. Comer, A. Campbell, Jermaine D. Jones, 2017, Addictive behaviors.

The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis

Thomas Chao, S. Comer, Jermaine D. Jones, 2023, Expert opinion on investigational drugs.

Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone

S. Comer, J. Manubay, Jermaine D. Jones, 2019, Pharmacology Biochemistry and Behavior.

The acute and repeated effects of cigarette smoking and smoking-related cues on impulsivity.

N. Vadhan, A. Bisaga, S. Comer, 2020, Drug and alcohol review.

Polydrug abuse: a review of opioid and benzodiazepine combination use.

S. Comer, Jermaine D. Jones, S. Mogali, 2012, Drug and alcohol dependence.

The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users

R. Ciccocioppo, M. Sullivan, S. Comer, 2016, Physiology & Behavior.

The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid‐dependent volunteers

M. Pavlicova, S. Vosburg, P. Saccone, 2016, Addiction Biology.

Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial

F. Levin, S. Comer, F. Yocca, 2023, The American journal of drug and alcohol abuse.

Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence

M. Sullivan, S. Comer, J. Manubay, 2017, Neuropsychopharmacology.

The effects of heroin administration and drug cues on impulsivity

N. Vadhan, S. Comer, Jermaine D. Jones, 2016, Journal of clinical and experimental neuropsychology.

Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone

S. Vosburg, Z. Cooper, M. Sullivan, 2013, PAIN®.

Need and utility of a polyethylene glycol marker to ensure against urine falsification among heroin users.

S. Comer, Jermaine D. Jones, V. Metz, 2015, Drug and alcohol dependence.

Objective and self-reported sleep outcomes in people with comorbid alcohol and opioid use disorder: examining the role of gabapentin

G. Zammit, S. Comer, Jermaine D. Jones, 2023, Journal of Substance Use.